Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021 ↗
Upgrades Citigroup upgraded the previous rating for Thor Industries Inc (NYSE: 
Via Benzinga
News headline image
Will This 2020 Biotech IPO Crush the Market This Year? ↗
Legend Biotech's CAR-T therapy's trial results were amazing, and could earn the treatment FDA approval in 2021. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Is bluebird bio's Surge a Bellwether for Gene Editing Stocks? ↗
With safety concerns allayed, the company is ready to restart clinical trials of key therapies. 
Via The Motley Fool
News headline image
BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
From bluebird bio, Inc.
Via Business Wire
News headline image
Bluebird bio Can Restart Halted Clinical Trials ↗
The FDA has lifted the hold on bluebird bio's gene-therapy studies in sickle cell disease and transfusion-dependent β-thalassemia. 
Via The Motley Fool
News headline image
bluebird bio to Present at Goldman Sachs Global Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
News headline image
Bluebird Bio Pops As FDA Allows In-Human Gene Therapy Testing To Resume ↗
The FDA removed a hold barring Bluebird Bio from testing its blood-disease gene therapies in people on Monday, and BLUE stock surged. 
Via Investor's Business Daily
News headline image
FDA Gives Signal to Halted Bluebird Bio's Gene Therapy Trials In Sickle Cell Disease, Thalassemia ↗
The FDA has lifted the clinical hold on Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of Bluebird Bio Inc's (NASDAQ: BLUE) LentiGlobin for sickle cell... 
Via Benzinga
News headline image
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
From bluebird bio
Via Business Wire
News headline image
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck ↗
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,... 
Via Benzinga
News headline image
bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)
From bluebird bio, Inc.
Via Business Wire
News headline image
Is bluebird bio a Buy for Summer 2021? ↗
With the stock down 54% over the past year, will investors be catching a falling knife if they buy now? 
Via The Motley Fool
News headline image
Bluebird bio's Neurological Disorder Gene Therapy Wins CHMP Backing for Approval ↗
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorizations for Bluebird bio Inc’s... 
Via Benzinga
News headline image
bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)
From bluebird bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers Enveric Biosciences (NASDAQ:ENVB)... 
Via Benzinga
News headline image
Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel) in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
bluebird bio to Present Data from Its Severe Genetic Disease and Oncology Portfolios During the EHA2021 Virtual Congress
From bluebird bio, Inc.
Via Business Wire
News headline image
NASDAQ:BLUE Long Term Investor Alert: Investigation of Potential Wrongdoing at Bluebird Bio Inc ↗
San Diego, CA -- (SBWIRE) -- 05/12/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of bluebird bio Inc. 
Via SBWire
Topics Lawsuit
News headline image
bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
News headline image
bluebird bio Announces May Investor Events
From bluebird bio, Inc.
Via Business Wire
News headline image
What Investors Need to Know About This $419,500 CAR-T Cancer Treatment ↗
Abecma is on the market. 
Via The Motley Fool
News headline image
Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock? ↗
The competition is starting to heat up, but bluebird is far from finished. 
Via The Motley Fool
News headline image
bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations
From bluebird bio, Inc.
Via Business Wire
News headline image
Is bluebird bio a Bad News Buy? ↗
The biotech has had a rough couple of years. 
Via The Motley Fool
News headline image
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.